Son Llàtzer University Hospital
If you are the contact person for this centre and you wish to make any changes, please contact us.
Researcher at the Endocrinology and Nutrition Service, Vascular and Metabolic Diseases Research Group, Hospital Universitario Son Llàtzer, Instituto de Investigación Sanitaria de las Islas Baleares (IdISBa)
Glucagon-like peptide-1 (GLP-1) receptor agonist drugs, used to control obesity and type 2 diabetes, are associated with changes in food purchasing in favour of healthier options. This result, published in the journal JAMA Network Open, was obtained by analysing nearly two million shopping receipts from more than 1,100 participants in Denmark. Those who started treatment with GLP-1 drugs began to make purchases with fewer calories, sugars, saturated fats and carbohydrates, along with a modest increase in protein content. A decrease in the purchase of ultra-processed foods was also observed.